Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer

Objective To investigate the effects of platinum-based first-line chemotherapy combined with irinotecan versus with etoposide on brain metastasis of small cell lung cancer patients (SCLC). Methods A retrospective analysis was carried out in 126 SCLC patients without brain metastases admitted to our...

Full description

Bibliographic Details
Main Authors: CHEN Weiling, , LI Xin, CHEN Zhujun, LIU Pan, TANG Chunlan, GONG Liang
Format: Article
Language:zho
Published: Editorial Office of Journal of Third Military Medical University 2020-03-01
Series:Di-san junyi daxue xuebao
Subjects:
Online Access:http://aammt.tmmu.edu.cn/Upload/rhtml/201910211.htm
_version_ 1818918446945009664
author CHEN Weiling
, LI Xin
CHEN Zhujun
LIU Pan
TANG Chunlan
GONG Liang
author_facet CHEN Weiling
, LI Xin
CHEN Zhujun
LIU Pan
TANG Chunlan
GONG Liang
author_sort CHEN Weiling
collection DOAJ
description Objective To investigate the effects of platinum-based first-line chemotherapy combined with irinotecan versus with etoposide on brain metastasis of small cell lung cancer patients (SCLC). Methods A retrospective analysis was carried out in 126 SCLC patients without brain metastases admitted to our hospital from November 2011 to July 2018, including 84 patients receiving irinotecan chemotherapy in the first line (IP group), and 42 patients undergoing etoposide treatment in the first line (EP group), both based on platinum treatment. Objective response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS), and cumulative incidence of central nervous system (CNS) and non-CNS progression after first-line treatment were compared between the 2 groups. Results For the IP group and the EP group, the ORR were 79.8% and 76.2%, respectively (P=0.645), and the DCR was 89.3% and 92.9%, respectively (P=0.748). The median PFS was 7.500±0.779 (5.974~9.026) months in the IP group, and 5.500±0.648 (4.230~6.770) months in the EP group, and statistical difference was seen between them (P=0.015). Compared with the EP group, the risk ratios of brain metastasis in IP patients with limited and extensive stages of SCLC were 0.270 (95%CI: 0.096~0.760, P=0.013) and 0.914 (95%CI: 0.281~2.973, P=0.881). In 3 months after treatment, the cumulative incidence of brain metastases in patients with limited stage was lower in the IP group than the EP group, and the incidence at 1 year was 14.3% and 31.8%, respectively. Conclusion IP chemotherapy delays the brain metastasis of SCLC patients when compared with EP treatment.
first_indexed 2024-12-20T00:50:06Z
format Article
id doaj.art-b416581bcb714df9b1f29ba46c83916f
institution Directory Open Access Journal
issn 1000-5404
language zho
last_indexed 2024-12-20T00:50:06Z
publishDate 2020-03-01
publisher Editorial Office of Journal of Third Military Medical University
record_format Article
series Di-san junyi daxue xuebao
spelling doaj.art-b416581bcb714df9b1f29ba46c83916f2022-12-21T19:59:17ZzhoEditorial Office of Journal of Third Military Medical UniversityDi-san junyi daxue xuebao1000-54042020-03-0142548749210.16016/j.1000-5404.201910211Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancerCHEN Weiling0, LI Xin1 CHEN Zhujun2LIU Pan3TANG Chunlan4GONG Liang5Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Objective To investigate the effects of platinum-based first-line chemotherapy combined with irinotecan versus with etoposide on brain metastasis of small cell lung cancer patients (SCLC). Methods A retrospective analysis was carried out in 126 SCLC patients without brain metastases admitted to our hospital from November 2011 to July 2018, including 84 patients receiving irinotecan chemotherapy in the first line (IP group), and 42 patients undergoing etoposide treatment in the first line (EP group), both based on platinum treatment. Objective response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS), and cumulative incidence of central nervous system (CNS) and non-CNS progression after first-line treatment were compared between the 2 groups. Results For the IP group and the EP group, the ORR were 79.8% and 76.2%, respectively (P=0.645), and the DCR was 89.3% and 92.9%, respectively (P=0.748). The median PFS was 7.500±0.779 (5.974~9.026) months in the IP group, and 5.500±0.648 (4.230~6.770) months in the EP group, and statistical difference was seen between them (P=0.015). Compared with the EP group, the risk ratios of brain metastasis in IP patients with limited and extensive stages of SCLC were 0.270 (95%CI: 0.096~0.760, P=0.013) and 0.914 (95%CI: 0.281~2.973, P=0.881). In 3 months after treatment, the cumulative incidence of brain metastases in patients with limited stage was lower in the IP group than the EP group, and the incidence at 1 year was 14.3% and 31.8%, respectively. Conclusion IP chemotherapy delays the brain metastasis of SCLC patients when compared with EP treatment.http://aammt.tmmu.edu.cn/Upload/rhtml/201910211.htmsmall cell lung cancerbrain metastasisirinotecantreatment
spellingShingle CHEN Weiling
, LI Xin
CHEN Zhujun
LIU Pan
TANG Chunlan
GONG Liang
Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer
Di-san junyi daxue xuebao
small cell lung cancer
brain metastasis
irinotecan
treatment
title Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer
title_full Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer
title_fullStr Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer
title_full_unstemmed Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer
title_short Effect of irinotecan combined with platinum first-line chemotherapy on brain metastasis of small cell lung cancer
title_sort effect of irinotecan combined with platinum first line chemotherapy on brain metastasis of small cell lung cancer
topic small cell lung cancer
brain metastasis
irinotecan
treatment
url http://aammt.tmmu.edu.cn/Upload/rhtml/201910211.htm
work_keys_str_mv AT chenweiling effectofirinotecancombinedwithplatinumfirstlinechemotherapyonbrainmetastasisofsmallcelllungcancer
AT lixin effectofirinotecancombinedwithplatinumfirstlinechemotherapyonbrainmetastasisofsmallcelllungcancer
AT chenzhujun effectofirinotecancombinedwithplatinumfirstlinechemotherapyonbrainmetastasisofsmallcelllungcancer
AT liupan effectofirinotecancombinedwithplatinumfirstlinechemotherapyonbrainmetastasisofsmallcelllungcancer
AT tangchunlan effectofirinotecancombinedwithplatinumfirstlinechemotherapyonbrainmetastasisofsmallcelllungcancer
AT gongliang effectofirinotecancombinedwithplatinumfirstlinechemotherapyonbrainmetastasisofsmallcelllungcancer